Poseida Therapeutics (PSTX) said Monday it is presenting new data analysis of potential allogeneic cell therapy P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma as well as new preclinical data supporting P-CD19CD20-ALLO1's anti-cancer profile.

Interim clinical data from its phase 1 trial of P-BCMA-ALLO1 showed a 91% overall response rate in the optimized lymphodepletion arm, with a 100% response in B-cell maturation antigen, or BCMA-naive patients, the clinical-stage biopharmaceutical company said, adding that the therapy showed favorable safety, with "no dose-limiting toxicities" and low rates of side effects.

Poseida said additional profiling of patient responses in the optimized lymphodepletion arm showed consistent P-BCMA-ALLO1 cellular expansion across patient subgroups, with an average manufacturing wait time of only 3.5 weeks.

The company also presented preclinical data for P-CD19CD20-ALLO1, an investigational allogeneic cell therapy for B-cell malignancies and Poseida's first dual CAR-T program, demonstrating "strong" antitumor activity.

Price: 9.45, Change: +0.09, Percent Change: +0.91